Ono Pharmaceutical Co (FRA:ON4) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ON4 Ono Pharmaceutical Co Ltd FRA:ON4
87 GF Score
Price €12.90
GF Value €12.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Ono Pharmaceutical Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:ON4
87GF Score
Ono Pharmaceutical Co Ltd FRA:ON4
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ono Pharmaceutical Co (FRA:ON4) Overvalued in 2026?

Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued. The current stock price of €12.90 is trading 6.6% above its estimated GF Value™ of €12.10. GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.

Key valuation signals for FRA:ON4:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €12.10 vs. price of €12.90 (6.6% above fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the FRA:ON4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ono Pharmaceutical Co Business Description

Other Exchanges OPHLY:USA4528:Japan
Address 1-8-2 Kyutarocho, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
87GF Score

Get the complete analysis for FRA:ON4

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.90
Price
€12.10
GF Value